|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II, Phase I
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
Perifosine 201 NCT00399789
|
|
|
|
|
|
|
|
Last Modified: 11/29/2005  First Published: 1/26/2003 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
CAN-NCIC-IND156 NCIC-156, NCT00053781, IND156
|
|
|
|
|
|
|
|
Last Modified: 3/16/2006  First Published: 1/26/2003 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
18 and over
|
|
|
|
NCI, Other
|
|
|
|
CAN-NCIC-IND155 NCIC-155, NCT00053794, IND155
|
|
|
|
|
|
|
|
Last Modified: 4/20/2007  First Published: 1/26/2003 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
PMH-PHL-015 NCI-5983, 5983, NCT00053924
|
|
|
|
|
|
|
|
Last Modified: 5/2/2007  First Published: 1/26/2003 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
PMH-PHL-014 NCI-5982, NCT00054145, 5982
|
|
|
|
|
|
|
|
Last Modified: 3/22/2008  First Published: 3/24/2003 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
Over 18
|
|
|
|
NCI
|
|
|
|
CCC-PHII-44 CHNMC-PHII-44-02166, NCI-5978, 5978, NCT00058214
|
|
|
|
|
|
|
|
Last Modified: 4/20/2007  First Published: 4/23/2003 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
ECOG-E1202 NCT00059982, E1202
|
|
|
|
|
|
|
|
Last Modified: 4/19/2006  First Published: 4/23/2003 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
NCI-03-C-0157 NCI-5970, NCT00060437
|
|
|
|
|
|
|
|
Last Modified: 7/16/2004  First Published: 5/23/2003 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
UCCRC-12198A NCI-5938, 5938, NCT00062387
|
|
|
|
|
|
|
|
Last Modified: 11/20/2006  First Published: 6/23/2003 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
MAYO-MC0276 NCI-5972, NCT00064324, 5972
|
|
|
|